Jazz Pharmaceuticals (JAZZ) Stock: Buy, Sell, or Hold?
JAZZ - Jazz Pharmaceuticals, Inc.
$245.80
5.32 (2.21%)
▲
5d:
-0.71%
30d:
-1.26%
90d:
+4.08%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JAZZ is fairly valued with market pricing in 3.5% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: JAZZ is fairly valued with market pricing in 3.5% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$257.10
Based on 3.5% avg growth
INTRINSIC VALUE TODAY
$159.64
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $245.80, which is considered slightly low relative to its 30-day fair value range of $244.14 to $255.89. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.3) compared to its historical average (8.4). At these levels, the market is pricing in 3.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is approaching resistance at $252.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $289.45 (+20.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is approaching resistance at $252.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $289.45 (+20.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$244.14 -
$255.89
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
Protect Your Profits
Holding JAZZ? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (46/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.4% below Wall St target ($289.45)
- NEUTRAL: Market pricing in 3.5% annual earnings growth - fairly valued
- NEUTRAL: Bottoming setup forming (46/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$244.14 -
$255.89
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$9.55
(3.9%)
Support & Resistance Levels
Support Level
$236.00
Resistance Level
$252.72
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.33
Wall Street Target
$289.45
(+20.4%)
Revenue Growth (YoY)
15.5%
Earnings Growth (YoY)
3.2%
Profit Margin
20.4%
Valuation Premium vs History
+3.5% premium
PE vs Historical
9.3 vs 8.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.5%
(market-implied from PE analysis)
1-Year Target
$248.90
(+4%)
2-Year Target
$257.61
(+7%)
3-Year Target
$266.62
(+11%)
3-Yr Target (if PE normalizes)
(PE: 9→8)
PE COMPRESSION
$240.01
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 3.0%)
$567.67
(+136%)
Base:
(SPY PE: 9.3, Growth: 3.0%)
$262.62
(+9%)
Bear:
(PE: 7.9, Growth: 3.0%)
$223.23
(-7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 16.51 | Current EPS (TTM): $14.62
Bull Case
$467.90
(+95%)
Analyst growth 76.3%, PE expands to 18.2
Base Case
$425.36
(+77%)
Market implied 76.3%, PE stable at 16.5
Bear Case
$164.09
(-32%)
Severe decline -20.0%, PE contracts to 14.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 11, 2026 4:21 PM ET
Data refreshes hourly during market hours. Next update: 5:21 PM
Data refreshes hourly during market hours. Next update: 5:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce C Cozadd
SELL
6000 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
